Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Individualized Brain Stimulation for Irritable Bowel Syndrome With Depressive Symptoms

Effects of Individualized Resting-State fMRI-Guided Intermittent Theta-Burst Stimulation on Depressive and Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome: A Randomized, Double-Blind, Sham-Controlled Trial

This randomized, double-blind, sham-controlled trial aims to evaluate the effects of individualized intermittent theta-burst stimulation (iTBS) on depressive and gastrointestinal symptoms in patients with irritable bowel syndrome (IBS) and depressive symptoms.

A total of 60 eligible participants will be randomly assigned in a 1:1 ratio to active or sham stimulation. Individualized stimulation targets within the left dorsolateral prefrontal cortex (DLPFC) will be identified using resting-state functional magnetic resonance imaging (fMRI).

Participants will receive 10 stimulation sessions over two weeks. Clinical assessments and multimodal brain MRI will be performed at baseline and at the end of Week 2. The primary outcome will be the change in depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAMD-17).

An optional ancillary study involving paired stool sample collection at baseline and Week 2 is planned to support future exploratory investigations of gut microbiota and its associations with clinical symptoms and brain network characteristics. This ancillary component will be implemented only after the relevant ethics approval and additional informed consent have been obtained.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310015
        • Rekruttering
        • The Affiliated Hospital of Hangzhou Normal University
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Right-handed individuals.
  • Diagnosis of irritable bowel syndrome according to the Rome IV criteria.
  • Presence of depressive symptoms, defined as a HAMD-17 score greater than 7.
  • Inadequate response to at least two months of conventional treatment for IBS.
  • Ability to understand the study procedures and provide written informed consent.
  • Willingness and ability to undergo MRI examinations and complete the study assessments.

Exclusion Criteria:

  • Contraindications to MRI or transcranial magnetic stimulation.
  • Known food intolerance, relevant gastrointestinal surgery, or gastrointestinal diseases other than IBS that may explain the symptoms.
  • History of significant neurological disorders or psychiatric disorders other than the depressive symptoms under investigation.
  • History of intracranial surgery.
  • Intracranial mass lesions or severe white matter abnormalities detected by MRI.
  • Other conditions that, in the investigator's judgment, would make participation inappropriate or unsafe.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Active Individualized iTBS

Participants will receive individualized intermittent theta-burst stimulation targeting the left dorsolateral prefrontal cortex. The stimulation target will be identified using resting-state fMRI-guided functional connectivity analysis.

Stimulation will be delivered at 90% of the resting motor threshold, with 1,800 pulses per session. Each session will comprise three blocks of 600 pulses, separated by approximately 15-minute intervals. Participants will receive five sessions per week for two weeks, for a total of 10 sessions.

Resting-state fMRI-guided iTBS targeting the individualized left dorsolateral prefrontal cortex at 90% of resting motor threshold, delivering 1,800 pulses per session for 10 sessions over two weeks.

Sham-komparator: Sham iTBS

Participants will undergo a sham stimulation procedure with a schedule comparable to the active intervention. The stimulation coil will be positioned at 90 degrees to minimize effective cortical stimulation.

Participants will receive five sessions per week for two weeks, for a total of 10 sessions.

A sham stimulation procedure using a coil positioned at 90 degrees, with a treatment schedule comparable to active iTBS.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in Depressive Symptom Severity Assessed by HAMD-17 at Week 2
Tidsramme: Baseline and end of Week 2

Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). A higher score indicates greater depressive symptom severity. The change from baseline to the end of Week 2 will be compared between the active and sham stimulation groups.

Baseline and end of Week 2

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in IBS Symptom Severity at Week 2
Tidsramme: Baseline and end of Week 2

IBS symptom severity will be assessed using the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS). Changes from baseline to the end of Week 2 will be compared between groups.

Baseline and end of Week 2
Change From Baseline in Abdominal Pain Intensity at Week 2
Tidsramme: Baseline and end of Week 2

Abdominal pain intensity will be evaluated using a Visual Analog Scale (VAS).

Baseline and end of Week 2
Change From Baseline in Pain Severity Assessed by the Short-Form McGill Pain Questionnaire at Week 2
Tidsramme: Baseline and end of Week 2

Pain-related symptoms will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ).

Baseline and end of Week 2
Change From Baseline in Anxiety Symptom Severity at Week 2
Tidsramme: Baseline and end of Week 2

Anxiety symptom severity will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14).

Baseline and end of Week 2
Change From Baseline in IBS-Related Quality of Life at Week 2
Tidsramme: Baseline and end of Week 2

IBS-related quality of life will be assessed using the Irritable Bowel Syndrome Quality of Life questionnaire (IBS-QOL).

Baseline and end of Week 2
MRI Outcomes
Tidsramme: Baseline and end of Week 2

functional and structural brain network analyses

Baseline and end of Week 2
Safety Outcomes
Tidsramme: Baseline and end of Week 2

adverse-event incidence

Baseline and end of Week 2

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. desember 2024

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

10. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere